Modulation of the amyloid-β (Aβ) trafficking pathway heralds a new therapeutic frontier for Alzheimer's disease (AD). As CD74 binds to the amyloid-β precursor protein (APP) and can suppresses Aβ processing, we investigated whether recombinant adeno-associated virus (AAV) delivery of CD74 could reduce Aβ production and affect disease outcomes. This idea was tested in a mouse AD model. Cotransduction of AAV-tetracycline-controlled transactivator (tTA) and AAV-tet-response element (TRE)-CD74 resulted in CD74 expression, reduced Aβ production in mouse neurons containing the human APP with familial AD-linked mutations. Stereotaxic injection of AAV-TRE-GFP or CD74 into the hippocampi of an AD mouse, defined as a TgCRND8 × calmodulin-dependent protein kinase II derived promoter-tTA double-transgenic, reduced Aβ loads and pyramidal neuronal Aβ accumulation in the hippocampus. Immunofluorescent studies showed that APP colocalization with Lamp1 was increased in CD74-expressing neurons. Moreover, Morris water maze tasks demonstrated that mice treated with AAV-TRE-CD74 showed improved learning and memory compared to AAV-TRE-GFP control animals. These results support the idea that CD74-induced alteration of Aβ processing could improve AD-associated memory deficits as shown in mouse models of human disease.
Aberrations in hippocampal neurogenesis are associated with learning and memory, synaptic plasticity and neurodegeneration in Alzheimer’s disease (AD). However, the linkage between them, β-amyloidosis and neuroinflammation is not well understood. To this end, we generated a mouse overexpressing familial AD (FAD) mutant human presenilin-1 (PS1) crossed with a knockout (KO) of the CC-chemokine ligand 2 (CCL2) gene. The PS1/CCL2KO mice developed robust age-dependent deficits in hippocampal neurogenesis associated with impairments in learning and memory, synaptic plasticity and long-term potentiation. Neurogliogenesis gene profiling supported β-amyloid independent pathways for FAD-associated deficits in hippocampal neurogenesis. We conclude that these PS1/CCL2KO mice are suitable for studies linking host genetics, immunity and hippocampal function.
Cyclic polymers are of increasing interest to the synthetic and physical polymer communities due to their unique structures that lack chain ends. This topological distinction results in decreased chain entanglement, lower intrinsic viscosity, and smaller hydrodynamic radii. Many methods for the production of cyclic polymers exist, however, large-scale production of architecturally pure cyclic polymers is challenging. Ring-expansion metathesis polymerization (REMP) is an increasingly promising method to produce cyclic polymers because of the mild and scalable reaction conditions. Herein, a brief history of REMP for the synthesis of cyclic polymers with both ruthenium and non-ruthenium initiators is discussed. Even though REMP is a promising method for synthesizing cyclic polymers, state-of-the-art methods still struggle with poor molar mass control, slow polymerization rates, low conversion, and poor initiator stability. To combat these challenges, our group has developed a tethered ruthenium-benzylidene initiator, CB6, which utilizes design features from ubiquitous Grubbs-type initiators used in linear polymerizations. These structural modifications are shown to improve initiator kinetics, enhance initiator stability, and increase control over the molar mass of the resulting cyclic polymers.1 Introduction2 Ring-Expansion Metathesis Polymerization (REMP) with Ruthenium Initiators3 New Developments in Ruthenium Ring-Expansion Metathesis (REMP) Initiator Design4 Ring-Expansion Metathesis Polymerization (REMP) with Non-Ruthenium Initiators5 Conclusions
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.